NCT02827370 is a NA clinical trial of Behavioral Dietary Intervention in Breast Carcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

What drugs are being tested in NCT02827370?

Interventions in NCT02827370: Behavioral Dietary Intervention.

What condition does NCT02827370 study?

NCT02827370 studies Breast Carcinoma.

Is NCT02827370 still recruiting?

NCT02827370 is currently completed. Last updated 29 April 2025.

Last reviewed 2025-04-29 · How we verify

NCT02827370

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CAREFOR: Precision Medicine Driving Precision Nutrition for the Treatment of NeoAdjuvant Breast Cancer

Completed NA Last updated 29 April 2025

What this trial tests

NA trial testing Behavioral Dietary Intervention in Breast Carcinoma in 26 participants. Completed in 15 December 2019.

Timeline

16 June 2016

Primary endpoint
1 July 2019

15 December 2019

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	16 June 2016
Primary completion	1 July 2019
Estimated completion	15 December 2019
Sites	1 location across United States

Drugs / interventions tested

Behavioral Dietary Intervention

Conditions studied

Breast Carcinoma — all drugs for Breast Carcinoma →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Who can join

18 and older, female only, with Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to determine if a targeted dietary change can enhance the effect of neo-adjuvant chemotherapy

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Dietary Interventions in Cancer Treatment and Response: A Comprehensive Review.
Mercier BD, Tizpa E, Philip EJ, Feng Q, et al · · 2022 · cited 28× · PMID 36291933 · DOI 10.3390/cancers14205149

Verify or expand the search:

Other trials of Behavioral Dietary Intervention

Trials testing the same drug.

NCT06733363 — A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscl · Phase 2 · recruiting
NCT06643455 — Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III Breast Cancer Survivors, MIND · NA · active not recruiting
NCT06315296 — An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Surviva · NA · terminated
NCT06030427 — Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors · NA · completed
NCT04548193 — Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship · Phase 1 · completed

Other recruiting trials for Breast Carcinoma

Currently open trials in the same condition.

NCT07067138 — A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS- · NA · recruiting
NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
NCT07338721 — Does Ultrasound Guidance Axillary Incision Improve Sentinel Lymph Node Detection in Breast Cancer? · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University trials

Trials by the same sponsor.

NCT06974981 — Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry · recruiting
NCT03796884 — Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer · Phase 2 · active not recruiting
NCT03712904 — Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma · Phase 2 · terminated
NCT03807492 — Evaluation and Management for Prostate Oncology, Wellness, and Risk (EMPOWeR) · completed
NCT03477864 — Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progres · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02827370 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Last refreshed: 29 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02827370.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing